Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
The Conversation logo

Smoking kills one in two regular smokers, but quitting at any point in life leads to big improvements in health, increased life expectancy and savings in healthcare costs. That’s why we need a range of ways to help people quit – and new evidence shows that paying people to quit is one way to boost quit rates.

Our recently updated Cochrane review looked at the evidence from 33 trials and found strong evidence that incentive programmes help people to quit smoking, increasing quit rates at six months or longer by about 50%. In these programmes, smokers who could prove they’d quit smoking were rewarded financially. Some have expressed concern that smokers would return to smoking once the financial rewards ended, but the studies showed that people stayed smoke free, even after the rewards finished.

Read the full article on The Conversation website, written by Jamie Hartmann-Boyce (Nuffield Department of Primary Care Health Sciences) and Caitlin Notley (University of East Anglia)

Oxford is a subscribing member of The ConversationFind out how you can write for The Conversation.

Similar stories

Just over half of British Indians would take COVID vaccine

Coronavirus COVID-19 General Research

University of Oxford researchers from the Department of Physiology, Anatomy and Genetics (DPAG) and the Department of Psychiatry, in collaboration with The 1928 Institute, have published a major new study on the impact of COVID-19 on the UK’s largest BME population.

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.

Parental mental health worsens under new national COVID-19 restrictions

Coronavirus COVID-19 General Research

Parental stress, depression and anxiety have again increased since new national restrictions have been introduced, according to the latest report from the Oxford University-led COVID-19 Supporting Parents, Adolescents, and Children in Epidemics (Co-SPACE) study, based on data from over 6000 UK parents.

£100 million donation from Ineos to create new institute to fight antimicrobial resistance

Awards and Appointments General Innovation

A new state of the art institute for antimicrobial research is to open at Oxford University thanks to a £100 million donation from Ineos.